111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血浆 MRGPRX2 与艾蒿诱导的变应性鼻炎严重程度相关，尤其在 IgE 阴性患者中：一项横断面研究
Authors Wang C, Wang N, Gong L, Du H, Luo S, Ji X, Yuan Y, Ding Y, Guan X, Liu R, Zhang T
Received 20 August 2025
Accepted for publication 4 December 2025
Published 13 December 2025 Volume 2025:18 Pages 1761—1772
DOI https://doi.org/10.2147/JAA.S561910
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Luis Garcia-Marcos
Chao Wang,1,* Na Wang,2,* Ling Gong,1 Hongfen Du,1 Shiqiong Luo,1 Xiaolan Ji,1 Yujuan Yuan,1 Yuanyuan Ding,1 Xukai Guan,3 Rui Liu,1 Tao Zhang1
1School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China; 2North China University of Science and Technology Affiliated Hospital, Tangshan, People’s Republic of China; 3Allergic Rhinitis Analysis and Testing Center, Central Laboratory, Science and Teach Department, Yulin Hospital, The First Affiliated Hospital of Xi’an Jiaotong University, Yulin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rui Liu, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China, Email rliu2018@xjtu.edu.cn Tao Zhang, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China, Email taozhang@mail.xjtu.edu.cn
Purpose: Mas-related G-protein-coupled receptor member X2 (MRGPRX2) is a key receptor in mast cell activation and plays a critical role in mediating pseudo-allergic reactions. However, its role in allergic rhinitis (AR) remains poorly understood. Therefore, we investigated the correlation between plasma MRGPRX2 and symptoms in AR patients.
Patients and Methods: A total of 116 patients with typical AR symptoms and positive skin prick test results and 100 healthy controls were recruited. Plasma MRGPRX2, total and specific IgE, and histamine were measured. AR patients who tested negative for both total IgE and sIgE were defined as IgE-negative. Symptom severity was evaluated using a questionnaire combining the Total Nasal Symptom Score (TNSS) and the Visual Analog Scale (VAS). TNSS assessed nasal (sneezing, rhinorrhea, congestion, itching), each scored from 0 (none) to 3 (severe). The VAS ranged from 0 cm (no symptoms) to 10 cm (most severe).
Results: Plasma MRGPRX2 levels were significantly elevated in patients with AR compared with healthy controls (P< 0.001) and demonstrated good discriminative performance (AUC=0.92, P< 0.001). Moreover, patients with moderate to severe AR had significantly higher plasma MRGPRX2 levels than those with mild AR (P< 0.001). A significant positive correlation was also observed between plasma MRGPRX2 levels and VAS scores (ρ=0.37, P< 0.001). This correlation was stronger in the IgE-negative AR group (ρ=0.61, P< 0.001) compared with the IgE-positive group (ρ=0.25, P=0.027) (Z=2.25, P=0.024). Notably, plasma MRGPRX2 levels were positively correlated with TNSS only in IgE-negative AR patients (ρ=0.38, P=0.016), whereas no significant correlation was observed in the IgE-positive group (ρ=0.17, P=0.238).
Conclusion: Plasma MRGPRX2 levels are elevated in patients with AR and are positively correlated with disease symptoms, particularly in IgE-negative cases. MRGPRX2 may serve as a novel biomarker to improve the classification and management of AR, especially in patients exhibiting allergic symptoms despite clinically insignificant IgE levels.
Keywords: allergic rhinitis, MRGPRX2, pseudo-allergic reaction, IgE
1School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China; 2North China University of Science and Technology Affiliated Hospital, Tangshan, People’s Republic of China; 3Allergic Rhinitis Analysis and Testing Center, Central Laboratory, Science and Teach Department, Yulin Hospital, The First Affiliated Hospital of Xi’an Jiaotong University, Yulin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rui Liu, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China, Email rliu2018@xjtu.edu.cn Tao Zhang, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an, People’s Republic of China, Email taozhang@mail.xjtu.edu.cn
Purpose: Mas-related G-protein-coupled receptor member X2 (MRGPRX2) is a key receptor in mast cell activation and plays a critical role in mediating pseudo-allergic reactions. However, its role in allergic rhinitis (AR) remains poorly understood. Therefore, we investigated the correlation between plasma MRGPRX2 and symptoms in AR patients.
Patients and Methods: A total of 116 patients with typical AR symptoms and positive skin prick test results and 100 healthy controls were recruited. Plasma MRGPRX2, total and specific IgE, and histamine were measured. AR patients who tested negative for both total IgE and sIgE were defined as IgE-negative. Symptom severity was evaluated using a questionnaire combining the Total Nasal Symptom Score (TNSS) and the Visual Analog Scale (VAS). TNSS assessed nasal (sneezing, rhinorrhea, congestion, itching), each scored from 0 (none) to 3 (severe). The VAS ranged from 0 cm (no symptoms) to 10 cm (most severe).
Results: Plasma MRGPRX2 levels were significantly elevated in patients with AR compared with healthy controls (P< 0.001) and demonstrated good discriminative performance (AUC=0.92, P< 0.001). Moreover, patients with moderate to severe AR had significantly higher plasma MRGPRX2 levels than those with mild AR (P< 0.001). A significant positive correlation was also observed between plasma MRGPRX2 levels and VAS scores (ρ=0.37, P< 0.001). This correlation was stronger in the IgE-negative AR group (ρ=0.61, P< 0.001) compared with the IgE-positive group (ρ=0.25, P=0.027) (Z=2.25, P=0.024). Notably, plasma MRGPRX2 levels were positively correlated with TNSS only in IgE-negative AR patients (ρ=0.38, P=0.016), whereas no significant correlation was observed in the IgE-positive group (ρ=0.17, P=0.238).
Conclusion: Plasma MRGPRX2 levels are elevated in patients with AR and are positively correlated with disease symptoms, particularly in IgE-negative cases. MRGPRX2 may serve as a novel biomarker to improve the classification and management of AR, especially in patients exhibiting allergic symptoms despite clinically insignificant IgE levels.
Keywords: allergic rhinitis, MRGPRX2, pseudo-allergic reaction, IgE